Thiruvananthapuram Researchers Secure ₹7 Crore for Cancer Device
A team at BRIC-RGCB has received significant funding to create a blood test for early cervical cancer detection.
The project aims to develop a non-invasive diagnostic device for cervical cancer.
Collaboration includes local startups and support from major health organizations.
The device will utilize advanced nanopore technology for analysis.
Researchers at the BRIC-Rajiv Gandhi Centre for Biotechnology (BRIC-RGCB) in Thiruvananthapuram have been awarded a grant of ₹7 crore to create an automated diagnostic device aimed at detecting early signs of cervical cancer through a simple blood sample. This innovative approach seeks to minimize the reliance on invasive procedures and specialized medical expertise, which can often limit access to timely diagnosis.
The initiative is a collaborative effort involving two startups: IndZita Biotech Pvt Ltd, based in Thiruvananthapuram, and Karkinos Healthcare Pvt Ltd located in Mumbai. This project is also backed by the MAHA MedTech Mission, a partnership that includes the Anusandhan National Research Foundation (ANRF), the Indian Council of Medical Research (ICMR), and the Gates Foundation, highlighting the significant interest and investment in improving cancer diagnostics in India.
Dr. Jackson James, the lead researcher on the project, emphasized the public health implications of cervical cancer in India. He noted that while early detection through screening is crucial, access to such services is often hampered by a shortage of trained personnel and adequate laboratory facilities. The goal of the new device is to extend diagnostic capabilities beyond specialized laboratory environments, making it more accessible to patients.
The proposed device will focus on identifying piRNA-based biomarkers present in blood samples, employing cutting-edge nanopore technology for analysis. This method promises to streamline the diagnostic process, allowing for quicker and more efficient identification of potential cervical cancer cases.
Looking ahead, the research team is optimistic about the device's development and validation timeline. Once completed, it is expected to revolutionize the way cervical cancer is screened in India, potentially leading to earlier interventions and better patient outcomes. The collaboration with startups and support from prominent health organizations underscores the importance of innovation in tackling public health challenges.
